Loading
Blood tests increasingly find precursor conditions like MGUS and smouldering myeloma, but most never progress. A registry with clear rules would stop early treatment outside trials.
Smouldering myeloma treatment trials prompt calls for early therapy, yet most patients would never progress; iStopMM (Iceland) shows population MGUS screening is feasible. Propose a national precursor registry (MGUS, smouldering myeloma, monoclonal B-cell lymphocytosis, CHIP) with risk stratification, no treatment outside trials, and patient-reported outcomes.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.
Shares Overdiagnosis in cancer, Overdiagnosis and false alarms.